Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The nicotinic acetylcholine receptor (nAChR), specifically the skeletal muscle type, is a ligand-gated ion channel located at the postsynaptic membrane of neuromuscular junctions in skeletal muscle. It is essential for converting chemical signals from motor neurons into electrical signals that trigger muscle contraction. The muscle-type nAChR is a heteropentamer composed of five subunits (two α1, one β1, one δ, and either one γ (fetal) or one ε (adult) subunit). When acetylcholine binds, it induces a conformational change that opens the central pore, allowing Na⁺ influx and K⁺ efflux, leading to muscle contraction. It is the target of drugs like curare derivatives, which are used as paralytics. Dysfunction is associated with myasthenia gravis.
Agonist binding opens the ion channel, allowing Na+ influx and K+ efflux, leading to depolarization and muscle contraction. Antagonists block the channel, preventing ion flow and muscle contraction.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nicotinic Acetylcholine Receptor (Skeletal Muscle Type) (nAChR (Skeletal Muscle)).